David Hutton

October 02, 2022

Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.

September 21, 2022

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

September 17, 2022

LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.

September 14, 2022

The American Academy of Ophthalmology annual meeting is coming to Chicago, Illinois, from September 30 to October 3, featuring Subspecialty Days and a virtual component.

September 11, 2022

Oral APX3330 was found to demonstrate favorable safety and tolerability profile in interim masked safety results, consistent with 11 prior trials of APX3330.

September 10, 2022

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

September 08, 2022

The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.

September 08, 2022

According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.

September 07, 2022

According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.

September 06, 2022

Researchers at the University of Bonn are evaluating a new imaging technique for the diagnosis of posterior uveitis.